

Charity Registration Number 1121784

Company Registration Number 06249601 (England and Wales)

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

(COMPANY LIMITED BY GUARANTEE)

TRUSTEES' REPORT AND UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2016

FRIDAY



A20 31/03/2017 #106
A63CAEH7
COMPANIES HOUSE

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

CONTENTS

	Page
Trustees' report	1 - 5
Statement of trustees' responsibilities	6
Accountants report	7
Statement of financial activities	8
Balance sheet	9
Notes to the accounts	10 - 14

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	A Budgen K Hill K Stubbs V Bridge R Hancock D Small
Secretary	A Budgen
Charity number	1121784
Company number	06249601
Principle address	Riverside East 2 Millsands Sheffield S3 8DT
Registered office	Riverside East 2 Millsands Sheffield S3 8DT
Accountants	Landin Wilcock & Co 68 Queen Street Sheffield S1 1WR
Bankers	CAF Bank 25 Kings Hill Avenue Kings Hill West Malling Kent ME19 4TA

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT

FOR THE YEAR ENDED 30 JUNE 2016

The trustees, who are also the directors of the charity for the purposes of the Companies Act, submit their annual report and the unaudited financial statements of the June Hancock Mesothelioma Research Fund for the year ended 30 June 2016. Reference and administrative information set out on page 1 form part of this report. The trustees confirm that these financial statements comply with current statutory requirements, in that they have complied with Section 17(5) of the 2011 Charities Act to have due regard to guidance published by the Charity Commission, and the small company regime (Section 419 (2) of the Companies Act 2006).

Structure, Governance and Management

The June Hancock Mesothelioma Research Fund is a registered charity (charity number 1121784) and a company limited by guarantee (company number 06249601).

The charity was incorporated on 16th May 2007 and is governed by its Memorandum and Articles of Association. This report covers the accounting period for the year ended 30th June 2016.

The trustees meet regularly to discuss the charity's progress and formulate general policy. They are ultimately responsible for the day-to-day management of the charity, including the making, enforcing and altering of rules, and the authority for all expenditure. Trustees are elected and/or re-elected in accordance with the provisions set out in the organisation's constitution. The current operational management of the charity is conducted by the Trustees together with the help of several volunteers under the guidance of the trustees.

All decisions of a management nature are made by the board of trustees, the quorum is fifty percent.

The income and property of the charity shall be applied solely towards the promotion of its objects as set forth in the Memorandum of Association. No portion thereof shall be paid or transferred, directly or indirectly, by way of bonus or otherwise by way of profit, to members of the charity. No member of the board of trustees shall be appointed to any office of the charity paid by way of salary or fees. Neither shall they receive any remuneration or other benefit in money or kind from the charity.

The trustees, (who are also the directors for the purposes of company law), who served during the year were:

**A Budgen
K Hill
K Stubbs
V Bridge
R Hancock
D Small**

None of the trustees has any beneficial interest in the company. All of the trustees are members of the company and guarantee to contribute £1 in the event of a winding up.

New trustees are appointed by a resolution of the existing trustees, and there is no requirement for trustees to retire annually and seek re-appointment. New trustees undertake an induction and training process that includes an interview with the existing trustees at which stage they are given a presentation of the charity's objectives and activities. They will also be provided with a bible of documents that includes strategy information, financial accounts, trustee minutes, publicity materials, key project information and Charity Commission information about the responsibilities of Charity Trustees.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

Risk assessment

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to these risks. The major risk to the charity is considered to be its reliance on donations and fund raising from the general public. A significant reduction in income would limit the development of the charity and the achievement of its objectives.

Objectives and activities

The objectives of the charity as described in its Memorandum are:

- Promoting research into the prevention, treatment, alleviation and cure of mesothelioma and other asbestos related conditions;
- Disseminating information about the said conditions (including but not limited to, the results of research funded by the JHMRF) for the benefit of the public provided that the objectives shall always be wholly and exclusively charitable.

The main policies undertaken through the financial year in furtherance of these objectives were:

- Accepting donations from those wishing to raise money specifically for research into mesothelioma. People who have encountered the disease in themselves or loved ones can take comfort from the knowledge that the money raised will fund research to help sufferers of the disease now and in the future.
- Providing high quality, easy to understand and up to date information on mesothelioma in publications and on our website. This includes information about the disease itself, treatments, clinical trials, novel therapies, where to go for more help, and also details of regional asbestos support groups.
- Supporting events like Action Mesothelioma Day to provide information to patients and carers, promote a better understanding of mesothelioma and raise awareness of the health implications of asbestos and asbestos products.
- Inviting applications for high quality mesothelioma research projects in the UK. All applications are independently reviewed and assessed by a panel of experts.

The trustees believe the above objectives and activities are clearly of value to mesothelioma patients and their carers, family and friends. The general public may also benefit from the results of research through prevention of this devastating disease. The trustees have had regard to the Charity Commission guidance on public benefit.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

Achievements and performance

No new grants were issued in the period July 2015 to 30 June 2016 but several JHMRF funded projects reported results. The project led by Professor Dean Fennell in Leicester has provided preliminary evidence for the role of the BRCA1 gene as a predictive biomarker for tailoring the chemotherapy treatment (vinorelbine) for individuals with mesothelioma. A research paper entitled "The BRCA1/MAD2L1 axis controls spindle poison-induced apoptosis and response to second line treatment with vinorelbine" has been submitted to Science Translational Medicine. The aim is to follow up on this important work, with a prospective biomarker study.

The study of CAR t-cells undertaken by Dr Astero Klabatsa at King's College London was completed in September 2015 and demonstrated proof of concept. The substantive study paper has been submitted and is awaiting publication.

The SYSTEMS 2 trial, the largest project grant awarded by the JHMRF since its inception, opened for recruitment. This multi-centre study aims to recruit around 200 patients to investigate the role of radiotherapy in controlling symptoms like pain. Mesothelioma is a condition with a high symptom burden thus this research is directly applicable to the care of patients and could lead to improvements in care in the shorter term.

The two JHMRF funded PhD fellows completed their transfer vivas successfully and pursuing their research studies at the Universities of Birmingham and Greenwich respectively.

The JHMRF annual 'Meet the Researchers' event took place on Action Mesothelioma Day in July 2015. It was held at Weetwood Hall in Leeds and was very well attended. It gives patients, their families and friends, and supporters of the JHMRF a unique opportunity to discuss ongoing research in mesothelioma with experts in a number of different fields, and to ask questions. Feedback from the participants was overwhelmingly positive and we plan to continue with this format in future years.

In March 2016, the JHMRF launched the third edition of the Mesothelioma Handbook. The original Mesothelioma Handbook was written by Mavis Robinson MBE with the intention of providing straightforward and comprehensive information for patients. Her commitment to improving care for people with mesothelioma was the foundation of the network of specialist nurses that exists today. The latest edition by Dr Helen Clayson, a long term advocate for mesothelioma patients, is based on her considerable experience of the medical and nursing care of people with mesothelioma and the support of their relatives. It provides a useful resource for patients and carers to 'dip in and out of'. There is also information for nurses and other healthcare professionals. The JHMRF provides copies free of charge to patients and informal carers as part of its commitment to supporting people affected by mesothelioma.

Financial review

The Fund has continued to receive some extremely generous donations throughout the year. Donations come mainly from people affected by the disease.

The level and number of awards that will be offered in the future will necessarily be determined by the availability and sustainability of funding. Funds will be set aside to support annual applications for pilot and feasibility studies, and for travel and educational awards. The next call for a major project award will be announced in due course.

Reserves Policy

The current level of reserves stands at £241,104. It is the policy of the charity to maintain unrestricted funds, which are the free reserves of the charity, the minimum level of reserves is £10,000. This provides sufficient funds to cover management and administration and support costs, as funds above this level will be available for the charity to support other projects in the future.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

Plans for the future


The charity will continue to pursue its main aim, which is to promote high quality research into mesothelioma in the UK. Over the coming year, the JHMRF will focus on raising funds for its next funding round both through donations and by seeking opportunities for funding partnerships. JHMRF aims to issue another call for major project proposals during the next twelve months.

The patient will remain at the heart of the JHMRF research strategy; mesothelioma is a disease with extremely poor outcomes and limited treatment options. Improving care for people with mesothelioma and increasing the range of therapeutic options available to them is a priority area for the fund. We aim to achieve this by building a strong and well-balanced portfolio of research, the outputs from which will be of real benefit to patients.

Mesothelioma is classed as an industrial disease and is caused by asbestos exposure. The JHMRF will work in partnership with other organisations like the HSE and the International Ban Asbestos Secretariat to raise awareness of asbestos in order to reduce the risk of people contracting mesothelioma in the future. The JHMRF will continue to support the call for a worldwide ban on the mining and manufacture of asbestos products, and recognises the need to seek more sustainable methods of providing employment and shelter for vulnerable populations in developing countries.

This report has been prepared in accordance with the provisions applicable to companies subject to the small company regime under section 419 (2) of the Companies Act 2006.

On behalf of the board of trustees



Adrian Budgen
Trustee



Dan Small
Trustee

Dated: 29th March 2017

Dated: 29th March 2017

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

STATEMENT OF TRUSTEES RESPONSIBILITIES FOR THE YEAR ENDED 30 JUNE 2016

Company law requires the trustees to prepare accounts for each financial year which give a true and fair view of the charitable company's state of affairs at the year end and of its income and expenditure for that period.

In preparing those accounts, the trustees are required to:

- select suitable accounting policies and apply them consistently;
- observe the methods and principles in the Charities SORP
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements
- prepare accounts on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the accounts comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

CHARTERED ACCOUNTANTS REPORT TO THE MEMBERS ON THE PREPARATION OF THE UNAUDITED ACCOUNTS OF THE JUNE HANCOCK MESOTHELIOMA RESEARCH FUND FOR THE YEAR ENDED 30 JUNE 2016

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the unaudited financial statements of June Hancock Mesothelioma Research Fund for the year ended 30 June 2016 which comprise the Statement Of Financial Activities, the Balance Sheet and the related notes from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at [icaew.com/members handbook](http://icaew.com/members/handbook).

This report is made solely to June Hancock Mesothelioma Research Fund board of directors, as a body, in accordance with our terms of engagement. Our work had been undertaken solely to prepare for your approval the financial statements of June Hancock Mesothelioma Research Fund and state those matters that we have agreed to state to June Hancock Mesothelioma Research Fund board of directors, as a body, in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its board of directors, as a body, for our work on this report.

It is your duty to ensure that June Hancock Mesothelioma Research Fund has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of its assets, liabilities, financial position and income of June Hancock Mesothelioma Research Fund. You consider that June Hancock Mesothelioma Research Fund is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of June Hancock Mesothelioma Research Fund. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.



Landin Wilcock & Co
68 Queen Street
Sheffield
S1 1WR

Dated: 29/8/2017

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

UNAUDITED STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 JUNE 2016

		Unrestricted funds	2016 Total	2015 Total
	Notes	£	£	£
<u>Incoming resources from generated funds</u>				
Investment income	2	4,205	4,205	4,796
Incoming resources for charitable activities	3	88,170	88,170	112,351
Other incoming resources		-	-	-
Total incoming resources		<u>92,375</u>	<u>92,375</u>	<u>117,147</u>
<u>Resources expended</u>				
Charitable activity costs	5	5,038	5,038	2,500
Governance costs	6	10,709	10,709	6,014
Research Grants & Costs	7	12,471	12,471	432,168
Total resources expended	4	<u>28,218</u>	<u>28,218</u>	<u>440,682</u>
Net incoming resources before transfers		64,157	64,157	(323,535)
Gross transfers between funds	10	-	-	-
Net income for the year		64,157	64,157	(323,535)
Fund balances at 1 July 2015		176,947	176,947	500,482
Fund balances at 30 June 2016	14	<u>241,104</u>	<u>241,104</u>	<u>176,947</u>

The results for the year derive from continuing activities and there were no income, resources expended or transfers with any Designated or Restricted Funds during the current or preceding financial period.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

UNAUDITED BALANCE SHEET AS AT 30 JUNE 2016

		2016	2015
	Notes	£	£
Current assets			
Investments	11	58,044	54,830
Debtors	12	36	36
Cash at bank and in hand		324,148	395,694
		<u>382,228</u>	<u>450,560</u>
Liabilities			
Creditors: amounts falling due within one year	13	720	908
Research Grants	7	4,000	136,301
Net current assets		<u>(4,720)</u>	<u>(137,209)</u>
Total assets less current liabilities		377,508	313,351
Creditors due after more than one year: Research Grants	7	136,404	136,404
Net Assets		<u><u>241,104</u></u>	<u><u>176,947</u></u>
Income funds			
Unrestricted funds		241,104	176,947
Accumulated funds	14	<u><u>241,104</u></u>	<u><u>176,947</u></u>


The company is entitled to exemption from audit under Section 477 (1) Companies Act 2006 for the year ended 30 June 2016.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2016 in accordance with Section 476 (1) of the Companies Act 2006.

The trustees acknowledge their responsibilities for ensuring that the charity keeps accounting records which comply with section 386 of the Act and preparing accounts which give a true and fair view of the state of affairs of the charity as at the end of the year and of its income and expenditure for the financial year. In accordance with the requirements of section 396 and which otherwise comply with the Companies Act 2006, so far is applicable to the charity.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small company regime, and with Financial Reporting Standard for Smaller Entities (effective January 2015).

The accounts were approved by the board on 29th March 2017 and were signed by:



Adrian Budgen
Trustee



Dan Small
Trustee

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 30 JUNE 2016

1 Accounting policies

1.1 Basis of preparation

The accounts have been prepared under the historic cost convention and in accordance with the statement of Recommended Practice Accounting and Reporting by Charities (SORP 2005).

The accounts have been prepared in accordance with applicable accounting standards, the 2011 Charities Act, the Companies Act 2006, and the Financial Reporting Standard for Smaller Entities (effective January 2015).

The charity has taken advantage of the exemption in Financial Reporting Standard 1 from the requirement to produce a cash flow statement on the grounds that it is a small company.

1.2 Incoming resources

Donations, legacies and other forms of voluntary income are recognised as incoming resources when they are receivable, except insofar as they are incapable of financial measurement.

1.3 Resources expended

Resources expended are included in the Statement of Financial Activities on an accruals basis, inclusive of any VAT which cannot be recovered.

Expenditure which is directly attributable to charitable activities has been included in this cost category.

Governance costs are those incurred in the management and operation of the charity's projects and charitable activities, together with any compliance costs.

1.4 Accumulated funds

Restricted funds are subject to specific conditions by donors as to how they may be used.

Unrestricted funds comprise funds that have been donated or generated through charitable activities which are not subject to any such usage conditions.

Designated funds are those either set aside by the trustees for specific purposes, or funds which are treated as such in order to follow accounting treatment guidelines as detailed within the Charities SORP 2005, and the 2011 Charities Act.

1.5 Investments

Investments are stated at market value at the balance sheet date.

2 Investment income

	2016 £	2015 £
Movement in valuation of investment	3,214	3,352
UK bank interest receivable	991	1,444
	<u>4,205</u>	<u>4,796</u>

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

3 Incoming resources for charitable activities

	2016 £	2015 £
Donations receivable	88,170	112,351

4 Total resources expended

	Other costs £	Total 2016 £	Total 2015 £
Charitable activity costs	5,038	5,038	2,500
Governance costs	10,709	10,709	6,014
Research Grants	12,471	12,471	432,168
	28,218	28,218	440,682

5 Charitable activity costs

	2016 £	2015 £
Fundraising and event expenditure	5,038	2,500
	5,038	2,500

6 Governance costs

	2016 £	2015 £
Printing and stationery	7,512	1,758
Accountancy & Professional fees	750	733
Bank charges	1,733	1,863
Trustees travel expenses	221	288
Miscellaneous expenses	493	1,372
	10,709	6,014

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

7 Research Grants

	2016 £	2015 £
Awarded in year:		
Projects and research fellowships	12,471	432,168
Charge in SOFA	12,471	432,168
Paid in the year	(144,772)	(249,022)
Movement	(132,301)	183,146
Balance at start of year	272,705	89,559
Balance at end of year	140,404	272,705
Due within one year	4,000	136,301
Due after more than one year	136,404	136,404
Balance at end of year	140,404	272,705

Grants awarded during the year:

Institution & Purpose of the Award	£
University of Greenwich - The JHMRF Fellowship, matched funding - A structure-activity study of JBIR-23 to determine the exact components required for activity against mesothelioma cell lines.	12,000
Student travel grants	471
	12,471

8 Trustees

No acting trustees (or any persons connected with them) received any remuneration during the year. One trustees travel expenses were reimbursed during the year totalling £221. (2015: Two trustees totalling £288)

9 Employees

Other than the trustees, the company had no employees.

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2016

10 Transfers

There was no income or resources expended by way of any Designated or Restricted Funds, hence there were no transfers between funds during the period.

11 Investments

	2016 £	2015 £
Quoted Investments		
Balance at start of year	54,830	51,477
Additions in the year	-	-
Movement in valuation of investment	3,214	3,353
Balance at end of year	<u>58,044</u>	<u>54,830</u>

This investment represents an investment bond. At 30 June 2016 the market value of the bond was £58,044.

12 Debtors

	2016 £	2015 £
Other debtors	<u>36</u>	<u>36</u>

13 Creditors: amounts falling due within one year

	2016 £	2015 £
Accruals	<u>720</u>	<u>908</u>

14 Analysis of net assets between funds

	Unrestricted funds £	2016 Total £	2015 Total £
Fund balances at 30 June 2016 are represented by:			
Tangible fixed assets	-	-	-
Current assets	382,228	382,228	450,560
Creditors: amounts falling due within one year	(4,720)	(4,720)	(137,209)
Creditors: amounts falling due after more than one year	(136,404)	(136,404)	(136,404)
	<u>241,104</u>	<u>241,104</u>	<u>176,947</u>

JUNE HANCOCK MESOTHELIOMA RESEARCH FUND

NOTES TO THE ACCOUNTS (CONTINUED) **FOR THE YEAR ENDED 30 JUNE 2016**

15 Contingent liabilities

There were no contingent liabilities as at 30 June 2016.

16 Capital commitments

There were no capital commitments as at 30 June 2016.

17 Post balance sheet events

There are no events after the balance sheet date which the trustees feel should be brought to the attention of the members.